Illumina closed its acquisition of SomaLogic on January 30 2026 for $350 million in cash, with the total transaction value potentially rising to $425 million when earn‑out and royalty payments are included. The deal gives Illumina ownership of SomaLogic’s SomaScan assay platform, SomaSignal tests, and a customer base that spans drug discovery, clinical research, and diagnostics.
The strategic goal of the purchase is to combine SomaLogic’s high‑plex proteomics technology with Illumina’s sequencing instruments, creating a unified multi‑omics platform that can generate genomic, epigenomic, and proteomic data from a single sample. The combined offering positions Illumina to capture a larger share of the projected $5 billion proteomics market, which is growing at roughly 15% annually, and to generate higher‑margin revenue streams from integrated services.
SomaLogic’s 2022 financials show $97.7 million in revenue but significant losses—$175.8 million operating loss and $109.2 million net loss—highlighting the valuation premium Illumina is paying for technology and customer relationships. Standard BioTools, the seller, reported a 34% decline in revenue over three years and a net margin of –67%, but the transaction leaves it with approximately $550 million in cash and a 2% royalty on SOMAmer‑based NGS library kits for ten years, providing a new revenue stream and financial flexibility for future growth initiatives.
Illumina CEO Jacob Thaysen said the acquisition “strengthens our multi‑omics strategy and expands our ability to deliver scalable insights across genomics and proteomics.” Standard BioTools CEO Michael Egholm noted the sale “positions the company to focus on mass cytometry and microfluidics while remaining well‑capitalized for future M&A.” The deal may attract regulatory scrutiny similar to the GRAIL acquisition, as it bundles Illumina’s dominant sequencing position with a leading proteomics platform, potentially raising antitrust concerns.
Analysts had mixed views on the transaction. Some praised Illumina’s ability to commercialize SomaLogic’s assets, while others questioned the strategic fit given existing partnerships and the presence of competitors such as Thermo Fisher’s Olink. The market reaction to the announcement on June 23 2025 was modest, reflecting cautious optimism about the integration and the competitive landscape.
The acquisition positions Illumina to compete more effectively in the multi‑omics space, but integration challenges—technology alignment, customer transition, and regulatory review—remain. Investors will likely focus on how the combined platform performs in the upcoming earnings call and whether Illumina can translate the added proteomics capability into incremental revenue and margin growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.